Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 586-588

  Keir, Stephen T ^a   Morton, Christopher L ^b   Wu, Jianrong ^b   Kurmasheva, Raushan T ^c   Houghton, Peter J ^c   Smith, Malcolm A ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Pazopanib; Preclinical testing

Indexed keywords

PAZOPANIB;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG INFORMATION; DRUG SCREENING; DRUG TOLERANCE; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TREATMENT DURATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MICE; MICE, SCID; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RHABDOMYOSARCOMA; SARCOMA, EWING; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863861217     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24016     Document Type: Article

References (18)

1. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9: 2-10.
2. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008; 9: 1324-1335.
3. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6: 2012-2021.
4. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2, 3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008; 51: 4632-4640.
5. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 475-480.
6. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010; 11: 962-972.
7. Taylor SK, Chia S, Dent S, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010; 15: 810-818.
8. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010; 28: 3562-3569.
9. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010; 12: 855-861.
10. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-3132.
11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
12. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2011; 77: 163-171.
13. van der Graaf WT, Blay J, Chawla SP, et al. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011; 29: (suppl; abstr LBA10002).
14. Houghton PJ, Morton CL, Tucker C, et al. The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
15. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD 2171 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 50: 581-587.
16. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 51: 42-48.
17. Keir ST, Maris JM, Lock R, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010; 55: 1126-1133.
18. Glade Bender JL, Lee A, Adamson PC, et al. Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL 0815): A Children's Oncology Group Phase I Consortium Trial. J Clin Oncol 2011; 29: (suppl; abstr 9501).